(R)-4-((4S,6S)-6-((2S,3E,6S,7E,10R)-13-((tert-butoxycarbonyl)amino)-6,10-bis((tert-butyldimethylsilyl)oxy)-2-hydroxytrideca-3,7-dien-1-yl)-2,2-dimethyl-1,3-dioxan-4-yl)-3-hydroxybutyl pivalate | 1290537-69-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (R)-4-((4S,6S)-6-((2S,3E,6S,7E,10R)-13-((tert-butoxycarbonyl)amino)-6,10-bis((tert-butyldimethylsilyl)oxy)-2-hydroxytrideca-3,7-dien-1-yl)-2,2-dimethyl-1,3-dioxan-4-yl)-3-hydroxybutyl pivalate
• 英文别名: [(3R)-4-[(4S,6S)-6-[(2S,3E,6S,7E,10R)-6,10-bis[[tert-butyl(dimethyl)silyl]oxy]-2-hydroxy-13-[(2-methylpropan-2-yl)oxycarbonylamino]trideca-3,7-dienyl]-2,2-dimethyl-1,3-dioxan-4-yl]-3-hydroxybutyl] 2,2-dimethylpropanoate
• CAS: 1290537-69-7
• 化学式: C₄₅H₈₇NO₁₀Si₂
• 分子量: 858.357
• InChiKey: DWNMDJBZEYYBTF-FUEHWOQMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.36
• 重原子数：
  58
• 可旋转键数：
  27
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  142
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  (R)-4-((4S,6S)-6-((2S,3E,6S,7E,10R)-13-((tert-butoxycarbonyl)amino)-6,10-bis((tert-butyldimethylsilyl)oxy)-2-hydroxytrideca-3,7-dien-1-yl)-2,2-dimethyl-1,3-dioxan-4-yl)-3-hydroxybutyl pivalate 、 叔丁基二甲基氯硅烷 在 咪唑 作用下， 以 1,2-二氯乙烷 为溶剂， 以97%的产率得到(R)-4-((4R,6R)-6-((2S,3E,6S,7E,10R)-13-((tert-butoxycarbonyl)amino)-2,6,10-tris((tert-butyldimethylsilyl)oxy)trideca-3,7-dien-1-yl)-2,2-dimethyl-1,3-dioxan-4-yl)-3-((tert-butyldimethylsilyl)oxy)butyl pivalate
  参考文献：
  名称：

  C(21)−C(40) of Tetrafibricin via Metal Catalysis: Beyond Stoichiometric Chiral Reagents, Auxiliaries, and Premetalated Nucleophiles

  摘要：

  The C(21)-C(40) fragment of fibrinogen receptor inhibitor tetrafibricin was prepared in 12 steps from propane diol (longest linear sequence). In this approach, 6 C-C bonds are formed via asymmetric iridium catalyzed transfer hydrogenative carbonyl allylation and 2 C=C bonds are formed via Grubbs olefin cross-metathesis.

  DOI：

  10.1021/ol200735r
• 作为产物：
  描述：

  4-(N-叔丁氧羰基氨基)-1-丁醇 在 咪唑 、 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 N-甲基咪唑 、 (S)-(-)-5,5-二氯-6,6-二甲氧基-2,2-双(二苯基磷酸)-1,1-联苯基 、 bis(1,5-cyclooctadiene)diiridium(I) dichloride 、 Hoveyda-Grubbs catalyst second generation 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 4-氯-3-硝基苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 93.0h， 生成 (R)-4-((4S,6S)-6-((2S,3E,6S,7E,10R)-13-((tert-butoxycarbonyl)amino)-6,10-bis((tert-butyldimethylsilyl)oxy)-2-hydroxytrideca-3,7-dien-1-yl)-2,2-dimethyl-1,3-dioxan-4-yl)-3-hydroxybutyl pivalate
  参考文献：
  名称：

  C(21)−C(40) of Tetrafibricin via Metal Catalysis: Beyond Stoichiometric Chiral Reagents, Auxiliaries, and Premetalated Nucleophiles

  摘要：

  The C(21)-C(40) fragment of fibrinogen receptor inhibitor tetrafibricin was prepared in 12 steps from propane diol (longest linear sequence). In this approach, 6 C-C bonds are formed via asymmetric iridium catalyzed transfer hydrogenative carbonyl allylation and 2 C=C bonds are formed via Grubbs olefin cross-metathesis.

  DOI：

  10.1021/ol200735r

文献信息

• C(21)−C(40) of Tetrafibricin <i>via</i> Metal Catalysis: Beyond Stoichiometric Chiral Reagents, Auxiliaries, and Premetalated Nucleophiles
  作者：Esa T. T. Kumpulainen、Byungsoo Kang、Michael J. Krische

  DOI：10.1021/ol200735r

  日期：2011.5.6

  The C(21)-C(40) fragment of fibrinogen receptor inhibitor tetrafibricin was prepared in 12 steps from propane diol (longest linear sequence). In this approach, 6 C-C bonds are formed via asymmetric iridium catalyzed transfer hydrogenative carbonyl allylation and 2 C=C bonds are formed via Grubbs olefin cross-metathesis.